Oncoinvent patent issues in the USA
Oslo 18. January 2017Oncoinvent announced today that US Patent 9,539,346 entitled ”Radiotherapeutic particles and suspensions” has issued. The patent relates to a particle or pharmaceutical composition comprising one or more particles, or a suspension of same or different particles comprising a degradable compound and an alpha emitting radionuclide and/or a radionuclide generating alpha emitting daughter. The particles are beneficial for use in the treatment of cancer. Jan A. Alfheim, Oncoinvent’s CEO commented: “This is a significant milestone in the development of our lead product